CA2373993C - Systeme de liaison specifique de site, compositions d'imagerie nucleaire et methodes y relatives - Google Patents

Systeme de liaison specifique de site, compositions d'imagerie nucleaire et methodes y relatives Download PDF

Info

Publication number
CA2373993C
CA2373993C CA002373993A CA2373993A CA2373993C CA 2373993 C CA2373993 C CA 2373993C CA 002373993 A CA002373993 A CA 002373993A CA 2373993 A CA2373993 A CA 2373993A CA 2373993 C CA2373993 C CA 2373993C
Authority
CA
Canada
Prior art keywords
emulsion
biotinylated
avidin
pbs
perfluorocarbon
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA002373993A
Other languages
English (en)
Other versions
CA2373993A1 (fr
Inventor
Gregory M. Lanza
Samuel A. Wickline
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Barnes Hospital
Original Assignee
Barnes Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Barnes Hospital filed Critical Barnes Hospital
Priority claimed from PCT/US1999/011491 external-priority patent/WO2000071172A1/fr
Publication of CA2373993A1 publication Critical patent/CA2373993A1/fr
Application granted granted Critical
Publication of CA2373993C publication Critical patent/CA2373993C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1806—Suspensions, emulsions, colloids, dispersions
    • A61K49/1812—Suspensions, emulsions, colloids, dispersions liposomes, polymersomes, e.g. immunoliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1217—Dispersions, suspensions, colloids, emulsions, e.g. perfluorinated emulsion, sols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1217—Dispersions, suspensions, colloids, emulsions, e.g. perfluorinated emulsion, sols
    • A61K51/1234—Liposomes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/585—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with a particulate label, e.g. coloured latex
    • G01N33/586—Liposomes, microcapsules or cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Optics & Photonics (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention concerne une méthode de liaison, basée sur des ligands, de particules à couche lipidique à des épitopes moléculaires sur une surface <u>in vivo</u> ou <u>in vitro</u>, cette méthode consistant notamment à administrer de manière séquentielle: a) un ligand spécifique de site activé par un agent activateur de biotine; b) un agent activateur d'avidine; et c) des particules à couche lipidique activées par un agent activateur de biotine, ledit ligand étant conjugué à ces particules par l'interaction avidine-biotine, le conjugué ainsi obtenu étant ensuite fixé aux épitopes moléculaires sur la surface susmentionnée. Ce conjugué peut être utilisé à des fins d'imagerie aux rayons X, aux ultrasons, par résonance magnétique, de tomographie par émission de positons, ou d'imagerie nucléaire. Cette invention concerne également des compositions employées dans les techniques d'imagerie nucléaire de surfaces naturelles ou synthétiques, ces compositions pouvant en effet servir à améliorer la réflectivité acoustique de ces surfaces.
CA002373993A 1999-05-25 1999-05-25 Systeme de liaison specifique de site, compositions d'imagerie nucleaire et methodes y relatives Expired - Fee Related CA2373993C (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US1999/011491 WO2000071172A1 (fr) 1997-12-12 1999-05-25 Système de liaison spécifique de site, compositions d"imagerie nucléaire et méthodes y relatives

Publications (2)

Publication Number Publication Date
CA2373993A1 CA2373993A1 (fr) 2000-11-30
CA2373993C true CA2373993C (fr) 2008-11-18

Family

ID=22272830

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002373993A Expired - Fee Related CA2373993C (fr) 1999-05-25 1999-05-25 Systeme de liaison specifique de site, compositions d'imagerie nucleaire et methodes y relatives

Country Status (3)

Country Link
JP (1) JP2003521475A (fr)
AU (1) AU771565B2 (fr)
CA (1) CA2373993C (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1651276A4 (fr) * 2003-08-08 2009-05-06 Barnes Jewish Hospital Particules d'emulsion destinees a l'imagerie et a la therapie et procedes d'utilisation de celles-ci
EP2708244A1 (fr) * 2012-09-14 2014-03-19 Stichting Katholieke Universiteit Agent de contraste et son utilisation pour l'imagerie

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5780010A (en) * 1995-06-08 1998-07-14 Barnes-Jewish Hospital Method of MRI using avidin-biotin conjugated emulsions as a site specific binding system
CZ75498A3 (cs) * 1995-09-18 1999-09-15 Mallinckrodt Medical, Inc. Radioaktivně značené deriváty biotinu

Also Published As

Publication number Publication date
JP2003521475A (ja) 2003-07-15
CA2373993A1 (fr) 2000-11-30
AU4097599A (en) 2000-12-12
AU771565B2 (en) 2004-03-25

Similar Documents

Publication Publication Date Title
US5958371A (en) Site specific binding system, nuclear imaging compositions and methods
AU710837B2 (en) Site specific binding system, imaging compositions and methods
US5690907A (en) Avidin-biotin conjugated emulsions as a site specific binding system
US5858399A (en) Acoustically reflective liposomes and methods to make and use the same
Lanza et al. In vitro characterization of a novel, tissue-targeted ultrasonic contrast system with acoustic microscopy
US7220401B2 (en) Blood clot-targeted nanoparticles
Tiefenauer et al. Antibody-magnetite nanoparticles: in vitro characterization of a potential tumor-specific contrast agent for magnetic resonance imaging
KR920010391B1 (ko) 핵자기 공명 조영제의 제조 방법
US6821506B2 (en) Site specific binding system, imaging compositions and methods
US20100209352A1 (en) Synthesis and conjugation of iron oxide nanoparticles to antibodies for targeting specific cells using fluorescence and mr imaging techniques
JPH07110815B2 (ja) 画像及びスペクトル向上（およびスペクトルシフト）のためのポリキレ−ト剤
US8440167B2 (en) Multimodal imaging of atherosclerotic plaque targeted to LOX-1
US6548046B1 (en) Site specific binding system, imaging compositions and methods
US20080247943A1 (en) Blood Clot-Targeted Nanoparticles
Demos et al. In vitro targeting of acoustically reflective immunoliposomes to fibrin under various flow conditions
CA2373993C (fr) Systeme de liaison specifique de site, compositions d&#39;imagerie nucleaire et methodes y relatives
AU2004202725B2 (en) Site specific binding system, nuclear imaging compositions and methods
Torchilin et al. Liposomes and micelles to target the blood pool for imaging purposes
JPH10509424A (ja) 磁気共鳴イメージングで顕著な効果を示すキレート錯体
Lanza et al. Development of a novel site-targeted ultrasonic contrast agent
Adzamli et al. Macromolecular infarct-specific magnetic resonance contrast agents
JPS60252429A (ja) Ｎｍｒイメージング用造影剤
Chan Nitroxide spin labels as NMR contrast agents: Delivery, metabolism and relaxation

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed
MKLA Lapsed

Effective date: 20110525